What is PDSB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PDSB?

P/E (TTM) is n/a and 52-week range is $0.20 to $1.55 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PDSB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PDSB?

The company profile lists net income (TTM) near $-36M, EPS (TTM) near $-0.65 when available from the market-data feed. Figures are informational and may lag live markets.

Where is PDS Biotechnology Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Princeton, New Jersey, US, 55.9M shares outstanding, ISIN US70465T1079 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

PDS Biotechnology Corp

$PDSB

Health Care · Biotechnology

IR Run Scenarios

$1.38

+35.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 21 full-time employees. The company went IPO on 2015-10-01. The firm is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

Employees

Website

www.pdsbiotech.com

IPO

2015-10-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)